- active not recruitingPHASE3
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
This study tested a new medicine, rilzabrutinib, for adults and teenagers with a blood condition called Immune Thrombocytopenia (ITP). It aimed to see if the medicine could help increase platelet counts, which are important for stopping bleeding.
United States · Argentina · Australia - active not recruitingPHASE1, PHASE2
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
This study looks at a new medicine called povetacicept for adults with rare blood conditions like Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (wAIHA), and Cold Agglutinin Disease (CAD). Researchers want to see if it's safe and helps improve these conditions.
United States · Australia · Austria - recruitingPHASE2
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
This study is looking at a new treatment called tafasitamab for adults with a type of autoimmune blood disorder called Immune Thrombocytopenia. Researchers want to see if it's safe, how well it works, and if it could be a helpful option for patients.
United States · Australia · France - authorisedHuman Pharmacology (Phase I)- Bioequivalence Study
A Phase 1, Randomized, Double-Blind, Two-Arm, Two-Way Crossover Study of Pharmacokinetics and Pharmacodynamics of QL0911
This study is looking at a new medicine, QL0911, for two conditions: Immune Thrombocytopenia (low platelets) and Acute Radiation Syndrome (a serious illness from radiation exposure). It's an early-stage study to understand how the medicine works in the body.
Poland - recruitingPHASE1
Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia
This study is looking at a new medicine called GL-2045 for people with Immune Thrombocytopenia (ITP). The main goal is to see if it's safe and helps increase platelet counts, similar to a treatment called IVIg.
United Kingdom - ongoing, recruitingPhase I and Phase II (Integrated)- Other
An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of Rilzabrutinib (PRN1008), an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenia
Czechia · Netherlands · Bulgaria - ongoing, recruitingPhase III and phase IV (Integrated)
Aspirin in immune thrombocytopenia patients with cardiovascular disease
France